1. Home
  2. WIA vs CHRS Comparison

WIA vs CHRS Comparison

Compare WIA & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Inflation-Linked Income Fund

WIA

Western Asset Inflation-Linked Income Fund

HOLD

Current Price

$8.25

Market Cap

197.8M

Sector

Finance

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.39

Market Cap

186.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WIA
CHRS
Founded
2003
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
197.8M
186.0M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
WIA
CHRS
Price
$8.25
$1.39
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$4.51
AVG Volume (30 Days)
39.2K
1.1M
Earning Date
01-01-0001
11-06-2025
Dividend Yield
12.29%
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.34
Revenue
N/A
$277,728,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$67.29
P/E Ratio
N/A
$1.01
Revenue Growth
N/A
152.07
52 Week Low
$7.56
$0.71
52 Week High
$8.91
$1.89

Technical Indicators

Market Signals
Indicator
WIA
CHRS
Relative Strength Index (RSI) 40.98 53.44
Support Level $8.19 $1.18
Resistance Level $8.29 $1.45
Average True Range (ATR) 0.06 0.09
MACD -0.00 0.03
Stochastic Oscillator 29.17 77.34

Price Performance

Historical Comparison
WIA
CHRS

About WIA Western Asset Inflation-Linked Income Fund

Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Share on Social Networks: